AN EQUAL OPPORTUNITY EMPLOYER RECEIVED UNITED STATES PATENT AND TRADEMARK OFFICE Washington, D.C. 20231
If Undeliverable Return In Ten Days MAR 2 2034 TECH CENTER 1600/2900 Official Business Renalty For Private Use, \$300

0210844208



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/529,397	09/26/2000	Shigeyuki Yokoyama	49651(1526)	7045
7590 03/12/2004 Peter F Corless Edwards & Angell			EXAMINER	
			WILDER, CYNTHIA B	
Dike Bronstein Roberts & Cushman IP Group			ART UNIT	PAPER NUMBER
130 Water Stree Boston, MA 0	• •		1637	
			DATE MAILED: 03/12/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	•	
	Application No.	Applicant(s)
	09/529,397	YOKOYAMA ET AL.
Office Action Summary	Examiner	Art Unit
	Cynthia B. Wilder, Ph.D.	1637
The MAILING DATE of this communication Period for Reply		the correspondence address
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, and If NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by so any reply received by the Office later than three months after the nearned patent term adjustment. See 37 CFR 1.704(b).	ON. R 1.136(a). In no event, however, may a repl a reply within the statutory minimum of thirty (; eriod will apply and will expire SIX (6) MONTH tatute, cause the application to become ABAN	ly be timely filed 30) days will be considered timely. IS from the mailing date of this communication. NDONED (35 U.S.C. § 133).
Status		
1)⊠ Responsive to communication(s) filed on 0	01 December 2003.	
- · · · · · · · · · · · · · · · · · · ·	This action is non-final.	
3) Since this application is in condition for allo	wance except for formal matter	s, prosecution as to the merits is
closed in accordance with the practice und	ler <i>Ex parte Quayle</i> , 1935 C.D. 1	11, 453 O.G. 213.
Disposition of Claims		
. 4)⊠ Claim(s) <u>19-35</u> is/are pending in the applic	ation	
4a) Of the above claim(s) is/are with		
5) Claim(s) is/are allowed.	arawn morn oonload allon.	
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) 19-35 are subject to restriction an	d/or election requirement.	
Application Papers		
9) The specification is objected to by the Exan	ninar	
10) The drawing(s) filed on is/are: a)		the Evaminer
Applicant may not request that any objection to		
Replacement drawing sheet(s) including the co		·
11) The oath or declaration is objected to by the		•
	y Examinor. Note the attached to	5/1100 / 10101/ 07 1011/1 1 TO 102.
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for fore	aign priority under 35 U.S.C. § 1	19(a)-(d) or (f).
a) All b) Some * c) None of:	and brown to a constant	
1. Certified copies of the priority docum		
2. Certified copies of the priority docum3. Copies of the certified copies of the priority documents.	• •	
application from the International Bu	•	cerved in this National Stage
* See the attached detailed Office action for a	, ,,,	ceived
	or the continue copies not re-	
attachment(s)		
)		nmary (PTO-413) Mail Date
B) Information Disclosure Statement(s) (PTO-1449 or PTO/SB		rmal Patent Application (PTO-152)
Paper No(s)/Mail Date	6) Other:	

U.S. Patent and Trademark Office

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Groups I, claim(s) 19-30, drawn to a nucleic acid, agent and method of using said nucleic acid.

Group II, claim(s) 32, drawn to a pharmaceutical composition.

Group III, claim(s) 33-35, drawn to method of selecting RNA.

2. The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The claims of Group I are sufficiently broad to encompass to encompass a nucleic acid taught in the prior art. Accordingly, the invention does not represent a contribution over the prior art because the prior art teaches a nucleic acid capable of being specifically bound to target protein of Ras (US 5,910,407, June 1999, col. 5, lines 2-8) as required by the invention of Group I. The claims lack a special technical feature that is the same or that corresponds to a special feature of the other claimed invention. Thus, there is not a special technical feature linking the recited groups, as would be necessary to fulfill the requirements for unity of invention.

Application/Control Number: 09/529,397

Art Unit: 1637

Further Groups I and II are drawn to distinct products lacking the same or corresponding technical feature special technical features. The nucleic acid of group I is composed of nucleotides and can function in methods of nucleic acid hybridization and/or amplification whereas the pharmaceutical composition of Group II functions as an agonist or antagonist and is administered to an organism as a treatment agent. Accordingly, the products mention above differ structurally and functionally from each other.

Further Group III drawn to a method of selecting RNA differs from the nucleic acid and method of using said nucleic acid of Group I and the pharmaceutical composition of Group II. The method of Group III have different objectives, method steps and results in a different effect than the invention of Group I or the composition of Group II. Therefore, it is again noted that the claims of the present invention are not directed to the same or corresponding special technical features for the reasons discussed above.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/529,397

Art Unit: 1637

80

Sequence Listing

- 4. The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821-1.825 for the following reasons(s): This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29 May 15, 1990 and at 55 FR 18230, May 1, 1990. Specifically, the specification contains sequences that are not represented by a sequence identifier (SEQ ID NO:); see pages 21, 23, 24, 25.
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cynthia B. Wilder, Ph.D. whose telephone number is (571) 272-0791. The examiner works a flexible schedule and can be reached by phone and voice mail. Alternatively, a request for a return telephone call may be emailed to cynthia.wilder@uspto.gov. Since email communications may not be secure, it is suggested that information in such request be limited to name, phone number, and the best time to return the call.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (703) 308-1119. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 09/529,397

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Cyntha Wilder

3/11/2007